MedWatch

Boehringer Ingelheim makes million-euro investment in fight against antibiotic resistance

The pharmaceutical firm is investing EUR 30m in a new biotech company focused on precision medicine to treat infections.

Photo: Boehringer Ingelheim / PR

German pharmaceutical firm Boehringer Ingelheim is investing EUR 30m to combat drug-resistant bacteria. Forming an alliance with Evotec and Biomérieux, the firms have established Aurobac Therapeutics, a biotech firm with a precision medicine approach to infection treatment, as reported by Fierce Biotech.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs